Last reviewed · How we verify
Pancrease MT 10.5, or MT 21
Pancrease MT is a pancreatic enzyme supplement used to treat exocrine pancreatic insufficiency.
Pancrease MT is a pancreatic enzyme supplement used to treat exocrine pancreatic insufficiency. Used for Exocrine pancreatic insufficiency.
At a glance
| Generic name | Pancrease MT 10.5, or MT 21 |
|---|---|
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Drug class | Pancreatic enzyme supplement |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
It works by replacing the pancreatic enzymes that the pancreas is unable to produce, helping the body to digest food properly. Pancrease MT contains a combination of lipase, amylase, and protease enzymes, which are essential for breaking down fats, carbohydrates, and proteins in the digestive system.
Approved indications
- Exocrine pancreatic insufficiency
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: